Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

Xilio Therapeutics (Nasdaq: XLO) will present new preclinical data for its masked T cell engager program targeting CLDN18.2 at the AACR Annual Meeting, April 17-22, 2026 in San Diego.

Rhea-AI Summary

Xilio Therapeutics (Nasdaq: XLO) will present new preclinical data for its masked T cell engager program targeting CLDN18.2 at the AACR Annual Meeting, April 17-22, 2026 in San Diego.

The poster, titled Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager, is scheduled for Monday, April 20, 2026, 9:00 a.m.–12:00 p.m. PST at Poster Section 10, Poster Board 11 (Abstract No. 1619).

Argus Mar 18 session

+2.29% close to close Open Argus

Details

News Market Reaction – XLO

In the Mar 18 session, XLO gained 2.29%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights new preclinical data for Xilio’s masked CLDN18.2-targeting T cell engag...

Analysis

This announcement highlights new preclinical data for Xilio’s masked CLDN18.2-targeting T cell engager XTX601, to be presented at AACR in April 2026. It reinforces earlier disclosures that emphasized a broad immuno-oncology pipeline and collaboration-driven programs. In context of recent financings, a reverse split, and extended cash runway, investors may watch for how such preclinical updates translate into clinical milestones, regulatory interactions, and partnership traction over time.

Key Figures

AACR meeting dates: April 17-22, 2026 Poster session date: April 20, 2026 Session time: 9:00 a.m.–12:00 p.m. PST +3 more

AACR meeting dates

April 17-22, 2026

American Association for Cancer Research Annual Meeting

Poster session date

April 20, 2026

XTX601 poster session date at AACR

Session time

9:00 a.m.–12:00 p.m. PST

AACR poster session window for XTX601

Poster section

Section 10

Location of XTX601 poster at AACR

Poster board

Board 11

Assigned poster board for XTX601

Abstract number

1619

AACR abstract identifier for XTX601 data

Historical Context

5 past events · Latest: Mar 12

5 events

1. Mar 12

   Reverse stock split

   24h Move

   -5.3%

   Announced 1-for-14 reverse split to support Nasdaq bid-price compliance.

2. Mar 02

   Conference participation

   24h Move

   +2.4%

   Planned fireside chat at Leerink Partners Global Healthcare Conference.

3. Mar 02

   Inducement grants

   24h Move

   +2.4%

   Granted 50,050 stock options to new employees under inducement plan.

4. Feb 11

   Equity financing

   24h Move

   +11.4%

   Priced pre-funded warrant offering for expected gross proceeds of $40M.

5. Jan 08

   Corporate update

   24h Move

   +2.6%

   Reported $137.5M cash, extended runway, and CLDN18.2 T cell engager milestone.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

t cell engager, cldn18.2, immuno-oncology

3 terms

t cell engager medical

"Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager"

A T cell engager is an engineered protein drug that physically links a patient’s T cell — the immune system’s attack cell — to a diseased cell so the T cell will recognize and kill it. For investors it matters because clinical trial results, manufacturing success and safety profiles determine whether the therapy becomes a widely adopted, high-value treatment or a costly failure; think of it like a matchmaker that must reliably bring soldiers to the right target without triggering friendly fire.

cldn18.2 medical

"masked T cell engager targeting <b>CLDN18.2</b>"

Cldn18.2 is a specific form of a protein that normally helps hold stomach cells together and, when present on the surface of cancer cells, acts as a visible marker for targeted treatments. Investors should care because drugs and tests that recognize cldn18.2 can selectively find and attack tumors—like a lock-and-key system—making it a focal point for developing therapies, clinical trials, and companion diagnostics that can drive revenue and valuation.

immuno-oncology medical

"developing masked immuno-oncology therapies for people living with cancer"

Immuno-oncology is a field of medicine focused on using the body's immune system to fight cancer. It involves developing treatments that help the immune system recognize and attack cancer cells more effectively. For investors, advancements in immuno-oncology can signal promising new therapies that may lead to improved patient outcomes and potentially significant commercial opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 17-22, 2026 at the San Diego Convention Center in San Diego, California.

Poster presentation details, as follows:

Title: Discovery and Optimization of XTX601, a Masked Claudin 18.2-Targeting T Cell Engager
Session Category: Immunology
Session Title: T Cell Engagers 1
Session Date and Time: Monday, Apr. 20, 2026, from 9:00 a.m. to 12:00 p.m. PST
Location: Poster Section 10
Poster Board: 11
Abstract Number: 1619

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Leveraging our clinically-validated masking technology and capabilities, Xilio is developing I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Learn more by visiting www.xiliotx.com and follow us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans to present data related to Xilio’s masked T cell engager program targeting CLDN18.2. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “seek,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks related to general market conditions and geopolitical uncertainties; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio’s current or future product candidates; Xilio’s need to obtain additional cash resources to advance its pipeline of tumor-activated I-O molecules; the impact of international trade policies on Xilio’s business, including U.S. and China trade policies; and Xilio’s ability to maintain its collaboration or partnership agreements with AbbVie, Gilead and Roche. These and other risks and uncertainties are described in greater detail in the sections entitled “Risk Factor Summary” and “Risk Factors” in Xilio’s filings with the SEC, including Xilio’s most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.

Investor Contact
Alex Lobo, Precision AQ
alex.lobo@precisionaq.com

Media Contact
Josie Butler, 1AB
josie@1abmedia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Xilio Therapeutics (XLO) present its XTX601 poster at AACR 2026?

Xilio will present on Monday, April 20, 2026, from 9:00 a.m. to 12:00 p.m. PST. According to the company, the poster session will be in Poster Section 10 at Poster Board 11 (Abstract No. 1619).

What preclinical data will Xilio (XLO) present about XTX601 at AACR 2026?

Xilio will present new preclinical results for XTX601, a masked Claudin 18.2-targeting T cell engager. According to the company, the poster covers discovery and optimization work supporting the program.

Where can investors find Xilio's (XLO) AACR poster details and abstract number?

The poster is listed as Abstract No. 1619 at Poster Section 10, Poster Board 11. According to the company, attendees can view the poster during the T Cell Engagers 1 session on April 20, 2026.

Is Xilio's XTX601 data clinical or preclinical in the AACR 2026 presentation?

The presentation is explicitly described as preclinical data for XTX601. According to the company, the poster focuses on discovery and optimization rather than clinical trial readouts.

What session will Xilio (XLO) appear in at the AACR Annual Meeting 2026?

Xilio's poster appears in the Immunology track within the T Cell Engagers 1 session. According to the company, the poster presentation is scheduled for April 20, 2026, during the morning poster session.